Research Project

Project Title:	PROTECT
Project Type:	Clinical Trial, Enrolment ongoing Adjunct biobank: Serum, Plasma, Urine
Disease group(s):	Immune glomerulopathies
Project Summary:	PROTECT is a Phase 3 trial in IgAN assessing the effect of Sparsentan on proteinuria and renal function against standard care (an angiotensin receptor blocker). PROTECT has the potential to define a valuable new treatment option and to shape clinical practice globally
Lead principal investigator(s):	Mai Rosenberg, Tartu
Co-investigator(s):	Kristi Veermäe, Tartu
Project Period:	10/2018 - 12/2023
Sponsors:	Industry
Project web page:	https://www.protectstudy.org.uk/
ClinicalTrials.gov:	NCT03762850